Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

Rhea-AI Summary

Prelude Therapeutics (NASDAQ: PRLD), a clinical-stage precision oncology company, has announced its participation in two major healthcare conferences in June 2025. CEO Kris Vaddi, Ph.D., will participate in fireside chats at the Jefferies Global Healthcare Conference on June 5 at 3:10 p.m. ET and at the Goldman Sachs 46th Annual Global Healthcare Conference on June 11 at 9:20 a.m. ET. Both presentations will be available via live webcast on the company's website and archived for 90 days. Prelude focuses on developing innovative medicines for cancer patients, with a pipeline including first-in-class SMARCA2 and KAT6A degraders, and is working on precision ADCs through partnerships.

WILMINGTON, Del., June 02, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June.

Jefferies Global Healthcare Conference 2025:
On Thursday, June 5, 2025, at 3:10 p.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude will participate in a fireside chat.

Goldman Sachs 46^th Annual Global Healthcare Conference:
On Wednesday, June 11, 2025, at 9:20 a.m. ET, Kris, Vaddi, Ph.D., Chief Executive Officer of Prelude will participate in a fireside chat.

Live webcasts of the fireside chats can be accessed on the Company’s website under Events and Presentations. The recordings will be archived and available on the Company’s website for 90 days.

About Prelude Therapeutics 
Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline is comprised of several novel drug candidates including first-in-class, highly selective SMARCA2 and KAT6A degraders, and ongoing research into other precision oncology targets. We are also leveraging our expertise in targeted protein degradation to discover, develop and commercialize next generation degrader antibody conjugates (Precision ADCs) with partners. We are on a mission to extend the promise of precision medicine to every cancer patient in need. Our corporate presentation can be found at Events & Presentations - Prelude Therapeutics. For more information, visit preludetx.com.

Investor Contact: 
Robert Doody
Senior Vice President, Investor Relations 
Prelude Therapeutics
484.639.7235
RDoody@preludetx.com

FAQ

When will Prelude Therapeutics (PRLD) present at the Jefferies Healthcare Conference 2025?

Prelude Therapeutics will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 3:10 p.m. ET.

Who will represent Prelude Therapeutics (PRLD) at the Goldman Sachs Healthcare Conference 2025?

Kris Vaddi, Ph.D., Chief Executive Officer of Prelude Therapeutics, will represent the company at the Goldman Sachs Healthcare Conference.

What type of drugs is Prelude Therapeutics (PRLD) developing?

Prelude Therapeutics is developing first-in-class SMARCA2 and KAT6A degraders, and precision degrader antibody conjugates (Precision ADCs) through partnerships.

How long will the webcasts of Prelude Therapeutics' (PRLD) conference presentations be available?

The webcasts of the fireside chats will be archived and available on the company's website for 90 days.